Bobby Reddy, Jr.

Bobby Reddy, Jr., Ph.D, has led Prenosis from inception by driving the company vision, building the team, securing clinical and strategic partnerships, and raising funds. He has more than a decade of experience in the research and development of early screening technologies for debilitating diseases with a deep understanding of clinical issues. For several years, Bobby has worked intimately with a wide variety of clinical and administrative hospital personnel to comprehensively understand how technology can address the most critical issues they face. He received a Ph.D. in electrical engineering from the University of Illinois at Urbana-Champaign, an M.S. in electrical engineering from the University of California, Irvine, and B.S. degrees in computer engineering and electrical engineering from the University of California, Irvine.

Prenosis Inc. is an artificial intelligence company enabling precision medicine in acute care. In April 2024, the U.S. Food and Drug Administration (FDA) granted marketing authorization for Prenosis’ Sepsis ImmunoScore using the De Novo pathway. The Sepsis ImmunoScore is an artificial intelligence/machine learning software as a medical device (AI SaMD) to guide rapid diagnosis and prediction of sepsis. It signified the first-ever FDA marketing authorization of an AI diagnostic tool for sepsis, an extremely complex condition that is difficult to diagnose early and has been a decades-long challenge for the U.S. healthcare system.